Resources from the same session
The first study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed or refractory low-grade gliomas
Presenter: Mark Kieran
Session: CNS tumours
Resources:
Abstract
Temporal muscle thickness (TMT) is an independent prognostic parameter in patients with newly diagnosed brain metastases (BM) of breast cancer (BC)
Presenter: Anna Sophie Berghoff
Session: CNS tumours
Resources:
Abstract
Survival of patients with synchronous and metachronous breast cancer and meningioma
Presenter: Catarina Ribeiro
Session: CNS tumours
Resources:
Abstract
Routine molecular subgrouping of medulloblastoma: Bridging the divide between research and the clinic using low-cost, mass spectrometry-based DNA methylomics
Presenter: Ed Schwalbe
Session: CNS tumours
Resources:
Abstract
Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
Presenter: Christian Grommes
Session: CNS tumours
Resources:
Abstract
PD-L1 and IL17 expression in tumor infiltrating lymphocytes are opposite prognostic factors in glioblastoma
Presenter: Estelle Bronsart
Session: CNS tumours
Resources:
Abstract
Invited discussant abstracts 329PD, 330PD and 331PD
Presenter: Deborah Blumenthal, MD
Session: CNS tumours
Resources:
Presentation
Webcast
Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM)
Presenter: Andrew Lassman
Session: CNS tumours
Resources:
Abstract
Effectiveness of antiangiogenic drugs (ADs) in glioblastoma (GBM) patients (PTS): a metanalysis of randomized clinical trials (RCTs)
Presenter: Giuseppe Lombardi
Session: CNS tumours
Resources:
Abstract
Clinical risk or molecular risk: What matters in low grade gliomas? A study from the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
Presenter: Enrico Franceschi
Session: CNS tumours
Resources:
Abstract